Urges U.S. President, Congress, and Department of Health and Human Services to ease patient limits applicable to private physicians prescribing buprenorphine as part of medication-assisted treatment for substance use disorders.
Impact
The bill addresses significant issues associated with the federal 'Controlled Substances Act' and its amendments under the Drug Addiction Treatment Act of 2000, which restricts the ability of physicians to prescribe buprenorphine to a limited number of patients. The resolution is grounded in research indicating that buprenorphine significantly lowers the risk of fatal overdose and promotes recovery, yet less than 32,000 physicians are presently authorized to prescribe it due to these federal regulations. This resolution aims to enhance the accessibility of buprenorphine treatment, potentially increasing the number of patients who can receive care, thus impacting the broader opioid crisis by promoting recovery supports.
Summary
SCR54 is a concurrent resolution introduced in the New Jersey Legislature that urges the President and Congress of the United States, along with the Department of Health and Human Services (DHHS), to ease current patient limits on private physicians prescribing buprenorphine. Buprenorphine is a medication used in treatment for opioid dependence, recognized for its ability to assist individuals in managing their addictions. The resolution specifically calls for the elimination of the 30-patient limit currently imposed under federal law for private physicians treating opioid-dependent patients. This limit is viewed as a barrier to effective treatment, as many individuals unable to access necessary care suffer from untreated addiction.
Contention
Notably, there are concerns surrounding the current regulations as they are deemed outdated by many experts and advocates. The legislation recognizes that despite the intent to prevent misuse, the existing patient limits likely impede treatment access more than they mitigate risks. Advocacy groups have pushed for reforms, stating that the federal restrictions reflect outdated prejudices against addiction, impeding the effective treatment of opioid use disorders. The resolution calls for legislative change to facilitate better care for those struggling with addiction, emphasizing that the inability of private physicians to adequately treat larger numbers of patients undercuts the potential for recovery in many individuals.
Health: substance use disorder treatment; substance use disorder services programs requirements; modify, and prohibit the promulgation of certain rules. Amends secs. 6230 & 6234 of 1978 PA 368 (MCL 333.6230 & 333.6234).
Resolutions urging the Congress of the United States to update the Drug Addiction Treatment Act of 2000 and remove excessive training requirements mandated for obtaining a waiver to prescribe buprenorphine
To Require The Department Of Human Services To Seek A Waiver To The Arkansas Medicaid Program For Coverage For Inpatient Treatment Services For Substance Use Disorders.
Increases access to substance use disorder treatment; Requires Medicaid coverage for substance use disorder services provided by community-based organizations.
Increases access to substance use disorder treatment; Requires Medicaid coverage for substance use disorder services provided by community-based organizations.
Modifying administrative rules relating to regulation of opioid treatment programs and requiring adjustments to the rates for substance use disorder treatment services with medications for opioid use disorder. (FE)
Modifying administrative rules relating to regulation of opioid treatment programs and requiring adjustments to the rates for substance use disorder treatment services with medications for opioid use disorder. (FE)
Residential Substance Use Disorder Treatment Act of 2023 This bill revises and reauthorizes through FY2027 grants for residential substance use disorder treatment programs at state and local correctional and detention facilities. Among the revisions, the bill replaces statutory references to substance abuse with substance use disorder, specifies that the term residential substance use disorder treatment program includes a medication-assisted treatment program, requires the chief medical officer or other staff overseeing a program to complete training on the science of addiction and the latest research and clinical guidance on treating substance use disorders in criminal justice settings, and allows people who are awaiting trial or in pretrial detention to participate in the programs.
Exempts any covered substance use disorder and mental health treatment services and all FDA approved medications for the treatment of substance use disorder, HIV, hepatitis C and mental health conditions, from all recipient restriction program coverage and payment restrictions.
Resolutions urging the Congress of the United States to update the Drug Addiction Treatment Act of 2000 and remove excessive training requirements mandated for obtaining a waiver to prescribe buprenorphine